Victoria M. Daddeo
FDA investigator
Appears on 1 document from 2017, mostly at sites in Massachusetts. Most often cites postmarketing reporting of adverse drug experiences (21 CFR 314.80).
- 1
- Documents on file
- 2.0
- Observations per 483
- 2017
- First seen
- 2017
- Most recent
What they cite most
From 2 observations- 21 CFR 314.80Postmarketing reporting of adverse drug experiences1
- 21 CFR 314.81Other postmarketing reports1
Activity by year
2017: 1
Where
Massachusetts 1
Often inspects with
Is Victoria M. Daddeo coming to your site?
Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.
Ask about any investigator in Claude or ChatGPT with the AI connector.
Inspection history
1 document, newest first| Date | Firm | Location | Observations | Open |
|---|---|---|---|---|
| 2017-05-31 | 483 ARIAD PharmaceuticalsMay 31, 2017 · Cambridge, Massachusetts | Cambridge, Massachusetts | 2 |
About this profile
What does Victoria M. Daddeo inspect?
Victoria M. Daddeo appears on 1 document on file covering 1 site, mostly in Massachusetts.
What do they cite most often?
21 CFR 314.80 (postmarketing reporting of adverse drug experiences), followed by 21 CFR 314.81.
Can I read the observations?
Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.
How current is this profile?
The most recent document on file for Victoria M. Daddeo is dated May 31, 2017.